Search research articles
Contact Us
Filters
Showing results (341-350 of 643) with videos related to
Page
of 65
Sort By:
Journal of the American College of Surgeons
|
April 5, 2005
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ
Tina W F Yen, Kelly K Hunt, Merrick I Ross, et al.
NPJ Breast Cancer
|
December 20, 2025
Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling
George W Sledge, Joanne Xiu, Reshma L Mahtani, et al.
Oncotarget
|
September 28, 2014
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan, Argun Akcakanat, Takafumi Sangai, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Annals of Surgery
|
January 8, 2013
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy
Elizabeth A Mittendorf, Thomas A Buchholz, Susan L Tucker, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Nature Methods
|
April 17, 2019
Integrated transcriptomic-genomic tool Texomer profiles cancer tissues
Fang Wang, Shaojun Zhang, Tae-Beom Kim, et al.
Oncotarget
|
May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
Ming-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2008
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach
Beth M Beadle, Wendy A Woodward, Susan L Tucker, et al.
Page
of 65
Search research articles
Search
Showing results (341-350 of 643) with videos related to
Sort By:
Page
of 65
Journal of the American College of Surgeons
|
April 5, 2005
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ
Tina W F Yen, Kelly K Hunt, Merrick I Ross, et al.
NPJ Breast Cancer
|
December 20, 2025
Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling
George W Sledge, Joanne Xiu, Reshma L Mahtani, et al.
Oncotarget
|
September 28, 2014
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Burhan Hassan, Argun Akcakanat, Takafumi Sangai, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Annals of Surgery
|
January 8, 2013
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy
Elizabeth A Mittendorf, Thomas A Buchholz, Susan L Tucker, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Nature Methods
|
April 17, 2019
Integrated transcriptomic-genomic tool Texomer profiles cancer tissues
Fang Wang, Shaojun Zhang, Tae-Beom Kim, et al.
Oncotarget
|
May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
Ming-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology
|
March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2008
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach
Beth M Beadle, Wendy A Woodward, Susan L Tucker, et al.
Page
of 65